Evidence map›Paper›PMID 11220405›Full record

ReviewPaediatric drugs2001

Caffeine citrate: a review of its use in apnoea of prematurity.

A M Comer, C M Perry, D P Figgitt

Abstract readReview
PubMed Publisher
In one paragraph

Review in Paediatric drugs, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 3 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 111 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Methylxanthine treatment for apnoea in preterm infants.The Cochrane database of systematic reviews · 2010
    Pooled it
  4. Trial
  5. Apnea of prematurity and caffeine pharmacokinetics: potential impact on hospital discharge.Journal of perinatology : official journal of the California Perinatal Association · 2016
    Trial
  6. High dose caffeine citrate for extubation of preterm infants: a randomised controlled trial.Archives of disease in childhood. Fetal and neonatal edition · 2004
    Trial
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Caffeine preserves quiet sleep in preterm neonates.Pharmacology research & perspectives · 2020
    Observational
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

A M ComerAdis International Limited, Auckland, New Zealand.
C M Perry
D P Figgitt

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledApnoea of prematurity is a common condition in neonates born at less than 37 weeks' gestational age; it affects approximately 90% of premature neonates weighing under 1000 g at birth, and 25% of infants with a birthweight of less than 2500 g. Caffeine, a methylxanthine which occurs naturally in many plants, has been used for over 20 years to treat apnoea of prematurity. In a recent double-blind, placebo-controlled trial, apnoea was eliminated or reduced by at least 50% in significantly more neonates receiving caffeine citrate as first-line treatment than those receiving placebo. In a nonblind trial, caffeine citrate was more effective at reducing apnoeic episodes when compared with neonates receiving no treatment. Caffeine as first-line treatment demonstrated similar efficacy to theophylline or aminophylline (theophylline ethylenediamine) in 4 small randomised studies. Caffeine citrate was generally well tolerated in short term clinical trials, with very few adverse events reported. Caffeine was associated with fewer adverse events than theophylline in randomised trials. No differences in the incidence of individual adverse events were reported between caffeine citrate and placebo in a double-blind, randomised trial. Long term tolerability data are not yet available.

conclusionsCaffeine citrate was generally well tolerated by neonates in clinical trials and it decreased the incidence of apnoea of prematurity compared with placebo. It has demonstrated similar efficacy to theophylline, but is generally better tolerated and has a wider therapeutic index. Caffeine citrate should, therefore, be considered the drug of choice when pharmacological treatment of apnoea of prematurity is required.

Indexed as

Infant, PrematureRandomized Controlled Trials as TopicApneaBrainCaffeineCentral Nervous System StimulantsCitratesDrug CombinationsHeart RateHumansInfant, NewbornRespirationCaffeinecaffeine citrateCentral Nervous System StimulantsCitratesDrug Combinations

Identifiers

PMID11220405
OpenAlexW2075649075

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.